This item requires a subscription to Clinical Cancer Research.
Full Text (PDF)
To view this item, select one of the options below:
Sign In
Purchase Short-Term Access
- Pay per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00.
- Pay for Admission - You may access all content in Clinical Cancer Research (from the computer you are currently using) for 1 day for US$50.00.
- Regain Access - You can regain access to a recent Pay per Article or Pay for Admission purchase if your access period has not yet expired.
Sign Up
- Subscribe to the Journal - Subscribe to the print and/or online journal.
This Article
-
Clinical Cancer Research May 15, 2009 15, 3366
- Show PDF in full window
- AbstractFree
- Full Text
- » Full Text (PDF)
Classifications
Services
Citing Articles
Google Scholar
Most
-
Read
- Hyperthermic Isolated Limb Perfusion with Tumor Necrosis Factor-{{alpha}} and Melphalan in Patients with Locally Advanced Soft Tissue Sarcomas: Treatment Response and Clinical Outcome Related to Changes in Proliferation and Apoptosis
- Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 Growth Factor Receptors and Their Ligands, Neuregulin-1 {{alpha}}, Neuregulin-1 {{beta}}, and Betacellulin, in Normal Endometrium and Endometrial Cancer
- Consideration of QT/QTc Interval Data in a Phase I Study in Patients with Advanced Cancer
- Imaging of Soft-Tissue Tumors Using L-3-[Iodine-123]Iodo-{{alpha}}-methyl-tyrosine Single Photon Emission Computed Tomography: Comparison with Proliferative and Mitotic Activity, Cellularity, and Vascularity
- Inhibition of PI3K and MEK: It Is All about Combinations and Biomarkers
-
Cited
- Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor
- Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase
- In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship
- Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
- A Novel Approach in the Treatment of Cancer: Targeting the Epidermal Growth Factor Receptor